Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

This study is ongoing, but not recruiting participants.

First Received: October 13, 2005 Last Updated: April 13, 2006 History of Changes

Sponsored by:	Pharmacology Research Institute
Information provided by:	Pharmacology Research Institute
ClinicalTrials.gov Identifier:	NCT00239954

Purpose

The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with major depressive disorder.

Condition	Intervention	Phase
Major Depressive Disorder	Drug: Escitalopram	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Fixed Dose Comparison of Escitalopram Combination in Adult Patients With Major Depressive Disorder

Resource links provided by NLM:

MedlinePlus related topics: Depression

Drug Information available for: Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by Pharmacology Research Institute:

Primary Outcome Measures:

Montgomery Asberg Depression Rating Scale (MADRS)

Secondary Outcome Measures:

Hamilton Depression Rating Scale (HAMD)

Study Start Date:

March 2005

Detailed Description:

Both active drugs being tested, alone and in combination, in this study are currently available antidepressants. However, the doses used in this study are lower than the standard approved doses.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both

Criteria

Inclusion Criteria:

Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder
The patient's current depressive episode must be at least 12 weeks in duration.

Exclusion Criteria:

Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.
Patients who currently meet DSM-IV criteria for : a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder.
Patients who are considered a suicide risk.
Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00239954

Locations

United States, California
Pharmacology Research Institute
Los Alamitos, California, United States, 90720
Pharmacology Research Institute
Newport Beach, California, United States, 92660
Pharmacology Research Institute
Northridge, California, United States, 91324
Pharmacology Research Institute
Riverside, California, United States, 92506

Sponsors and Collaborators

Pharmacology Research Institute

Investigators

Principal Investigator:	Jon F. Heiser, MD	Pharmacology Research Institute
Principal Investigator:	Nader Oskooilar, MD	Pharmacology Research Institute

More Information

No publications provided

Study ID Numbers:	PRI#591 & #592
Study First Received:	October 13, 2005
Last Updated:	April 13, 2006
ClinicalTrials.gov Identifier:	NCT00239954 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Neurotransmitter Agents
Depression
Cholinergic Antagonists
Psychotropic Drugs
Depressive Disorder, Major
Depressive Disorder
Cholinergic Agents
Serotonin Uptake Inhibitors
Citalopram

Serotonin
Behavioral Symptoms
Muscarinic Antagonists
Mental Disorders
Mood Disorders
Peripheral Nervous System Agents
Antidepressive Agents, Second-Generation
Dexetimide
Antidepressive Agents

Additional relevant MeSH terms:

Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Psychotropic Drugs
Antiparkinson Agents
Depressive Disorder, Major
Cholinergic Agents
Pathologic Processes
Mental Disorders
Therapeutic Uses
Dexetimide

Antidepressive Agents, Second-Generation
Antidepressive Agents
Disease
Depression
Depressive Disorder
Serotonin Uptake Inhibitors
Citalopram
Pharmacologic Actions
Behavioral Symptoms
Muscarinic Antagonists
Serotonin Agents
Autonomic Agents
Mood Disorders
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 02, 2009